Mo Elzek

Physician Scientist. founder @lonlongevity. First principle biology = targeting aging.

[Mo Elzek @moelzek]

We had a blast in Athens! 🇬🇷 Last week, we brought @LongHackathons to Athens, working alongside some incredible partners AthensLifeTech Park and @EndeavorGr to run the country's first life sciences hackathon alongside Panathēnea. A huge thank you to everyone who supported especially our great sponsors at Dyania Health, @pfizer Thessaloniki, @Lovable , and @Azure

[Mo Elzek @moelzek]

Longevity needs a story.

We are premiering Forever Young, an award winning documentry filmed over three years, three continents, features @prof_horvath, @NirBarzilaiMD, Eric Verdin, and 20 others leading longevity giants. Followed by live Q&A with David Donnelly and @chiara_herzog.

📍 Imperial College Business School, London
🗓 3 June 2026, 6:00pm
🎟 Free to attend. Link below!

Satellite event for the @foresightinst 's Vision Weekend UK (5–7 June), a week of longevity conversations in London.

Cohosted by @LonLongevity, London Ageing Research Network, Imperial Aging & Longevity Society, and Imperial Medtech Society

[Mo Elzek @moelzek]

Immune enhancement, cancer resistance, and DNA repair keeps coming up in many human and animals models of aging

[Aging Science News @AgingBiology]

The Greenland shark genome: Insights into lifespan extremes and population dynamics
https://t.co/x6XEuZC0cO

[Mo Elzek @moelzek]

@cgeorgiaw @prasithg cool! thank you!

[Mo Elzek @moelzek]

@cgeorgiaw @prasithg I have the same question. Can you point me to the blogpost please?

[Mo Elzek @moelzek]

It is still early in longevity. 700 orgs only

[Rob Sheko @RobSheko]

I’m excited to launch the Longevity Biotech Atlas, a personal project mapping 700+ organizations across the aging and longevity ecosystem.

Longevity biotech is moving fast.

A lot of the public narrative has centered on GLP-1s, peptides, biohacking, and consumer health optimization. But beneath that, a much deeper ecosystem is forming: companies, labs, investors, and non-profits working on core technologies that will enable fundamentally new forms of measurement and rejuvenation.

The field is growing quickly, but it is still hard to answer basic questions:
Who is building what?
Which areas are crowded?
Which technologies are underexplored?
Where should founders, scientists, investors, and operators be paying attention?

To help make the space easier to navigate, I synthesized public information on 700+ organizations—ranging from therapeutics developers, diagnostics, investors, and more— into a single database.

You can explore the atlas at the link in the comments.

This is still an early version, and I’ll be adding more over time: new organizations, personal accounts, bookmarks, and better ways to track how the field is evolving. My hope is to build this out into a core tool for people trying to understand, build, fund, or work in longevity.

If you’re interested in aging biology, biotech, investing, company formation, or the future of medicine, follow along. I’ll be sharing updates, maps of different subfields, and analyses of where the biggest opportunities and gaps may be. Let me know what you find useful!

[Seth Bannon @sethbannon]

No more Phase 1, 2, or 3 in clinical trials?

The FDA is proposing using AI to get trial data in real-time from EHRs and giving trial design feedback based on what it sees.

No more batch processing could eliminate the wait between phases and get therapies to market faster.

[Georgia Channing @cgeorgiaw]

🤗🤗🤗introducing Hugging Science -- the home of AI for science 🤗🤗🤗

open models and datasets are the powerhouse of science (see the PDB), but finding the models and data you actually need for your breakthrough is hard af

you shouldn't need to scrape arxiv, own your own wetlab, fight a custom HDF5 parser, build a fusion stellarator, and beg for compute before you've trained a single epoch

so we're changing that

we've put all the best science on @huggingface in one place:
- 78GB of genomics data
- 11TB of PDE simulations
- 100M cell profiles
- 9T DNA base pairs
- 13M molecular trajectories
- 400k medical QA pairs

and much more, all open, and all ready for training (+ you can also now filter and search by domain, task, and keyword)

we've put together all the biggest releases from our partners at NASA, Google, OpenAI, Meta FAIR, Arc Institute, Ginkgo, SandboxAQ, Proxima Fusion, NVIDIA, Ai2, OpenADMET, InstaDeep, Future House, Polymathic AI, LeMaterial, Earth Species Project, Merck, and Eve Bio

if you're not sure where you fit in -- work on open challenges for problems that matter: including fusion stellarator design, ADMET, antibody developability, multilingual medicine, catalysis and materials, and scientific reasoning.

we're already changing how science gets done:

a fusion startup needed a benchmark for stellarator plasma confinement that didn't exist. @proximafusion shipped ConStellaration on Hugging Science: a leaderboard, dataset, and eval metrics, all in one place.

a drug discovery team wanted to predict hPXR induction. OpenADMET put up a blind challenge: 11,000+ compounds assayed at Octant, 513 held out, two tracks (pEC50 + structure). Anyone in the world can train and submit.

an antibody team at @Ginkgo released GDPa1, a developability dataset for stability, manufacturability, and immunogenicity prediction, with a live leaderboard scoring every submission.

if you know a problem the ML community should be working on, let us know. make a challenge! this is about putting all the tools for solving science in one place. so we can hillclimb!

→ https://t.co/T4l4r1lDz0

[Mo Elzek @moelzek]

Two reports covered in the UK media yesterday point to the same thing.
1. The UK is now sicker for longer.
The The Health Foundation reported that healthy life expectancy has dropped from 64 to 61 over the past decade, meaning the last working years of ageing now include more sickness.

2. More Britons will die each year than are born.
The Office for National Statistics confirmed that 2026 will be the first year since World War I in which deaths outnumber births in the UK, a trend that will continue.

Economies around the world are ageing into deficit.
This is the biggest problem of this century. Not fewer resources, but fewer people.

Unfortunately, this is not reversible by progressive fertility policy reforms. Children do not enter the workforce overnight; it takes two decades, and they also take their parents out of the workforce.

That leaves one option: radical extension of the healthy and productive years of the people already alive.

Last week, I had the chance to make the economic case on @LSEnews stage. Longevity is not vanity, and it is not wishful thinking by some billionaires. It is a demographic emergency that needs to have fiscal reforms.

For decades, countries have pushed pension age to offset the consequences of ageing populations. But it will not matter much if the last few years before pension are spent sick. Pension age should be tied to the healthy lifespan a country is able to provide, not merely chronological age.

Longevity is hyped for the wrong reasons; supplements, clinics, and wearables are a $300 billion industry. In contrast, longevity biotech is the only way to push healthy lifespan, but it is less than $1 billion (10 times less than pet skincare). That is a market failure.

Despite this, the science is advancing quickly. Some rejuvenation and senolytic therapies are in clinical trials. Some might argue that GLP-1 drugs are a glimpse of what a “longevity” intervention looks like, with effects on heart, kidneys, liver, brain, ovaries, joints, and addiction, all besides their impact on weight loss and diabetes (their current indications). The numbers make this clear. Scratching the potential of its market (currently ~2%), GLP-1 drugs generated around $70 billion in 2025, compared to $30 billion that AI chatbots like OpenAI and Anthropic made combined last year.

It is not a competition with AI. The purpose of technology has always been to create abundance; more, cheaper, better. AI does that for intelligence.
But AI will not give you another decade with your parents.
It will not pay your country’s pensions.
AI is a tool, but the endgame is human life.

Thanks to @LSESU_Startups for the invitation and the great organisation.

[Mo Elzek @moelzek]

Daniel is such a great scientist!

[Robert Lufkin MD @robertlufkinmd]

I've had a lot of remarkable conversations on Health Longevity Secrets, but this one stayed with me differently.

Dr. Daniel Ives, Ph.D., CEO and founder of Shift Bioscience, is one of the clearest thinkers I've encountered in the longevity space — and one of the most honest. He's honest about failure. Honest about uncertainty. And honest about the fact that the mountain he's climbing keeps looking bigger the closer he gets.

https://t.co/OMf9XJTOrF

[Mo Elzek @moelzek]

Literally the best place to meet people who want to do something about ageing!

[Nathan S. Cheng thinks you should work on aging. @realNathanCheng]

1/ How long do you want to live?

For most of human history, aging was inevitable.

It's now solvable.

Apply for LBF8 cohort program: longbiofellowship dot org

/THREAD🧵

[Nathan S. Cheng thinks you should work on aging. @realNathanCheng]

1/ How long do you want to live?

For most of human history, aging was inevitable.

It's now solvable.

Apply for LBF8 cohort program: longbiofellowship dot org

/THREAD🧵

[Mo Elzek @moelzek]

@MariaRostovsk @The_MRC @GurdonInstitute @Cambridge_Uni Congrats Maria 👏👏

[Michael Florea @MichaelFloreaX]

@NucleateHQ and @EliLillyandCo are launching a 100k non-dilutive grant for aging.

This is a pretty good opportunity if you're early and building around longevity.

Repost and tag a friend. Deadline: May 15

Details in the first comment.

[David J Glass MD @davidjglassMD]

Years in the making: a detailed aging gene signature in mice and rats. >30 tissues, high Ns, multi-time points throughout the lifespan. >5000 samples in total. The data is accessible, so you check to see if your favorite gene is age-regulated.

https://t.co/5heN6ixvt1

[Mo Elzek @moelzek]

@longevityboris Thanks for sharing this @longevityboris

[Mo Elzek @moelzek]

Great news!!

[Human Longevity, Inc @humanlongevity]

The Godfather of AI just joined our mission to help humanity live past 100. Nobel Laureate Geoffrey Hinton has joined @humanlongevity as a Scientific Advisor — bringing the mind behind modern AI to the frontier of longevity medicine.

https://t.co/6ZuJiRa1u7

[NVIDIA Healthcare @NVIDIAHealth]

🚀 The largest-ever open‑source protein‑complex treasure trove - 1.7 million of AI‑predicted complexes now live in the AlphaFold Database

In collaboration with @emblebi, @GoogleDeepMind, and @SeoulNatlUni, we have added millions of predicted complexes to the AlphaFold Database to accelerate global health research.
🧵👇

[London Longevity Network @LonLongevity]

Looking to have deep and honest conversations about drug discovery?

Five tables facilitated by pioneers from industry, academia, and startups. Ten seats each. One hard problem per table. Pick your problem and come join
🧵